Piramal Critical Care (PCC), a division of Piramal Pharma Limited, has announced the introduction of a new concentration of Zinc Sulfate for Injection USP in the U.S. market. This 10mg/10mL (1 mg/mL) concentration is a strategic addition to PCC’s existing Zinc Sulfate Injection product line and overall generic injectables portfolio.

Addressing Pediatric Nutritional Needs with Zinc Sulfate Injection

Zinc Sulfate is a critical trace element used in parenteral nutrition, especially when oral or enteral nutrition is not feasible. The new 1 mg/mL concentration is particularly tailored for pediatric patients, including those weighing less than 26 pounds. This expansion in the product line demonstrates PCC’s commitment to addressing the diverse needs of patients in the U.S.

CEO Peter DeYoung on PCC’s Mission and Product Expansion

Peter DeYoung, Chief Executive Officer of Piramal Global Pharma, expressed excitement about the launch. “The introduction of the 10mg/10mL Zinc Sulfate for Injection aligns with our mission of supplying crucial medications. This launch not only expands our U.S. portfolio but also complements our market-leading inhaled anesthesia offerings,” he said.

Piramal Critical Care’s Growing Injectable Product Portfolio

The new Zinc Sulfate concentration joins a series of recent product launches by Piramal Critical Care, including Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP. These introductions reinforce PCC’s position as a key player in the generic injectables market, catering to a range of critical care needs.

This launch signifies Piramal Critical Care’s ongoing effort to meet the growing demands of the healthcare sector, especially in the realm of critical care and pediatric nutrition. With a focus on innovation and patient-centric solutions, PCC continues to make significant strides in the pharmaceutical industry.

  Peter DeYoung, Piramal Critical Care, Piramal Pharma, USA, Zinc Sulfate Injection